Corning Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? Corning Incorporated trades at $162.49 (market cap $135.89B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Corning Incorporated is the larger of the two by market cap, and Corning Incorporated pays the higher dividend (0.71%). Which is the better fit depends on your goals.
| GLW | REGN | |
|---|---|---|
Market Cap | $135.89B | $83.19B |
Sector | Technology | Health |
52-Week High | $255.79 | $812.27 |
52-Week Low | $64.52 | $555.51 |
Enterprise Value | $142.77B | $77.90B |
Dividend Yield | 0.71% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
GLW trades at $165.69, up 5.41% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $15.63B in 2025, with net income surging to $1.60B. The stock is supported by AI-driven optical demand and analyst optimism, though valuation multiples like a P/E of 76.35 appear elevated. Recent news highlights partnerships with major tech firms and a strategic focus on photonics expansion.
The outlook for GLW is positive, driven by AI infrastructure growth and a $10B photonics goal, but risks include high valuation sensitivity and execution challenges. Analysts project a 16.6% upside to the $193.33 consensus target, with 57% recommending buy. Investors should weigh robust fundamentals against premium pricing and competitive pressures in the semiconductor supply chain.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →